Next Article in Journal
A Comment on Qi et al. An Estimation of Radiobiological Parameters for Head-and-Neck Cancer Cells and the Clinical Implications—Authors' Reply
Previous Article in Journal
Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
Previous Article in Special Issue
Association of Differentiation-Related Gene-1 (DRG1) with Breast Cancer Survival and in Vitro Impact of DRG1 Suppression
Cancers 2013, 5(1), 1-11; doi:10.3390/cancers5010001
Article

Clinical Significance of CK19 Negative Breast Cancer

1,* , 1, 1, 2, 1, 1, 3 and 3
Received: 5 November 2012; in revised form: 17 December 2012 / Accepted: 19 December 2012 / Published: 21 December 2012
(This article belongs to the Special Issue Breast Cancers: Pathology and Biomarkers)
View Full-Text   |   Download PDF [608 KB, uploaded 21 December 2012]   |   Browse Figure
Abstract: Analysis of sentinel lymph nodes (SLNs) by means of One-Step Nucleic Acid Amplification (OSNA) is gaining widespread use as a quick and accurate method. This assay detects the expression level of cytokeratin 19 (CK19) which is present in some but not all breast tumors. In this study, the clinical significance of negative CK19 was investigated in 219 cases of primary breast cancer. In 179 patients with clinically negative nodes, OSNA and imprint smear cytology of SLN were performed simultaneously. The OSNA revealed a node-positive rate of 24.6%. Negative CK19 correlated significantly with negative ER/PgR and higher Ki-67 values, and marginally with higher nuclear grade and p53 overexpression. The triple negative subtype showed lower CK19 expression. OSNA revealed that one of the negative CK19 cases was actually a false negative but this was corrected with the use of the imprint smear cytology. In conclusion, CK19 negativity reflected the aggressiveness of primary breast cancer. OSNA assay used to analyze SLN was useful, but there is a possibility that it will mistakenly detect false negatives in CK19 negative tumors. Therefore, in tumors with negative CK19, the imprint smear cytology may be more useful in cases with macrometastasis.
Keywords: breast cancer; OSNA; CK19; imprint smear cytology; sentinel lymph node; Ki-67; p53 breast cancer; OSNA; CK19; imprint smear cytology; sentinel lymph node; Ki-67; p53
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Fujisue, M.; Nishimura, R.; Okumura, Y.; Tashima, R.; Nishiyama, Y.; Osako, T.; Toyozumi, Y.; Arima, N. Clinical Significance of CK19 Negative Breast Cancer. Cancers 2013, 5, 1-11.

AMA Style

Fujisue M, Nishimura R, Okumura Y, Tashima R, Nishiyama Y, Osako T, Toyozumi Y, Arima N. Clinical Significance of CK19 Negative Breast Cancer. Cancers. 2013; 5(1):1-11.

Chicago/Turabian Style

Fujisue, Mamiko; Nishimura, Reiki; Okumura, Yasuhiro; Tashima, Rumiko; Nishiyama, Yasuyuki; Osako, Tomofumi; Toyozumi, Yasuo; Arima, Nobuyuki. 2013. "Clinical Significance of CK19 Negative Breast Cancer." Cancers 5, no. 1: 1-11.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert